drugset / Trial / NCT04539236
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Phase 1/2
Suspended
50 enrolled
Mikkael Sekeres MD
Bristol-Myers Squibb · collabCelgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate if the combination of drugs, Lenalidomide and Luspatercept, will help improve the treatment of anemia in patients with lower-risk Myelodysplastic Syndrome (MDS).
Timeline
- Start
- 2021-11-09
- Primary completion
- 2029-08-01
- Completion
- 2029-08-01
Outcome
Outcome not reported
Stopped (Business): “Funding Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 2.5 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 5 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Luspatercept | Protein / enzyme biologic | 1.75 mg/kg | Subcutaneous |